In an ASX announcement dated 18 August 2026, Cochlear Limited (ASX:COH) presented its FY26 results. Cochlear develops cochlear implants, bone conduction and acoustic implants. The release covers the operational and financial review for the year, the company’s strategic priorities, the FY27 outlook, cash flow, dividends and a reconciliation of constant currency net profit.

This article summarises those details, the sector context, the risks the company identifies and the next steps indicated.

Press Release Details

Sales Revenue was $2,343.4 million, down 1 per cent as reported and up 2 per cent in constant currency, with constant currency growth of 6 per cent in the second half. Underlying net profit was $322.4 million, down 22 per cent, and statutory net profit was $147.3 million, down 62 per cent. Underlying Earnings Per Share were $4.93, compared with $6.33. Gross Margin fell from 74 per cent to 71 per cent, which the company attributed to sales mix (1.5 percentage points), Manufacturing variances (1.2 percentage points) and foreign exchange (0.6 percentage points).

Operating expenses were $1,251.4 million, up 5 per cent, including $69 million of transitional costs: $32 million of restructuring costs and a $37 million replenishment of the short-term incentive provision. Comparable operating expenses declined 1 per cent, while Research and Development expenses rose 15 per cent. The difference between underlying and statutory profit reflects significant items after tax of $66.0 million for cloud computing-related expense and $109.1 million of non-cash fair value, share of losses and Impairment on investments, primarily Epiminder.

By segment, cochlear implant revenue was $1,435.2 million, flat in constant currency, on units that rose 5 per cent to 56,692. Services revenue was $634.9 million, up 6 per cent in constant currency, and Acoustics revenue was $273.3 million, up 1 per cent. Cochlear said the Nucleus Nexa System accounted for more than 95 per cent of implant sales across developed markets by June and achieved an average 3 per cent price increase. Regionally, US revenue increased 4 per cent, Western Europe declined 8 per cent, Asia Pacific rose 7 per cent and emerging markets declined 2 per cent in constant currency.

Free Cash Flow rose $141 million to $264 million, and net cash decreased $88 million to $188 million. The final Dividend is $1.30 per share, 85 per cent franked, taking total dividends to $3.45 per share, down 20 per cent, representing a payout of 70 per cent of underlying net profit. The ex-dividend date is 21 September 2026, the Record Date is 22 September 2026 and payment is expected on 14 October 2026.

For FY27, Cochlear expects low single-digit constant currency sales revenue growth and underlying net profit of $330 million to $350 million. Assumptions include gross margin of about 70 to 71 per cent, research and development of about 13 per cent of sales revenue, Capital Expenditure of $100 million to $110 million and an AUD/USD rate of 70 cents. The company states that at those rates a higher Australian dollar is expected to reduce underlying net profit by about 10 per cent relative to FY26 average rates.

The release describes three priorities: reducing fixed costs, which creates capacity for $25 million of additional growth Investment in FY27; accelerating the medicalisation of hearing loss to strengthen adult referral pathways; and building on the Nexa platform. It notes that medical and professional referrals account for only 40 per cent of adult cochlear implant referrals in the United States.

Sector Backdrop

The release describes the long-term opportunity in hearing implants as supported by low penetration and increasing awareness of the health consequences of untreated hearing loss, including links to cognitive decline. It notes that adult segment growth has historically been around 10 per cent per annum, but that the adult segment remains dependent on non-medical referral channels and patient self-navigation.

Cochlear points to developed market conditions in FY26 that included insurance approval delays and economic pressures on healthcare in the United States, elective surgery backlogs in the United Kingdom and industrial action in Spain. In emerging markets, it cites conflict in the Middle East and volume-based procurement and reimbursement reductions in China.

Risks Shareholders Should Weigh

The announcement records several negatives alongside its guidance. Underlying and statutory profit both fell, gross margin declined three percentage points, and the net profit margin of 14 per cent was below the medium-term 18 per cent target. Cochlear says current trading conditions remain mixed and that many of its actions will take time to translate into more consistent growth.

Foreign exchange is a quantified risk: movements reduced FY26 underlying net profit by 8 per cent, or $24 million, and hedging smooths timing but does not fully offset sustained currency movements. FY27 guidance includes a roughly 10 per cent reduction from a higher Australian dollar.

Other factors cited include China pricing, the Middle East conflict, a maturing sound processor replacement cycle that is expected to slow Services growth, further restructuring costs in FY27, completion of the cloud program with about $60 million after tax still to be reported as a significant item, and the Volatility of innovation fund investments.

What’s Next

The company expects to expand ENT education and referral pilots from four major US cities to 12 over the coming months, with Germany and Australia to follow, and to deploy software updates for the Nexa System over the coming months. The Osia 3 Sound Processor is expected to launch in the first half of FY27.

The final dividend is expected to be paid on 14 October 2026. Cochlear’s medium-term aim is a net profit margin of 18 per cent, and the release states the dividend policy continues to target a payout of 70 per cent of underlying net profit.